CTLA4 and non-small cell lung carcinoma: For example, ipilimumab-NF (BMS-986218) is a next-generation anti-CTLA4 antibody with increased activity in preclinical studies that is currently being tested alone or in combination with nivolumab in various tumors, including NSCLC (NCT03110107).